PAM Pathway
Overactivation of the PAM (PI3K/AKT/mTOR) pathway plays a key role in the progression of a wide variety of human cancers.
REVTORPYK™ (gedatolisib) is FDA-approved as a 2nd-line treatment for HR+/HER2-PIK3CA wild-type advanced breast cancer.
Our Pipeline
We are evaluating gedatolisib across a range of solid tumors to improve patient outcomes.
Clinical Trials
We have multiple ongoing clinical trials for gedatolisib as a potential treatment for breast and prostate cancer.
Recent News
October 24, 2026
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
October 23, 2026
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
October 5, 2026
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026